- All News
- In the News
- Press Releases
- Noteworthy Articles
Biocartis & Immunexpress Sign Partnership for a Sepsis Host Immune Response Test on the Idylla™ platform
Mechelen (Belgium)/Seattle (United States), 24 January 2018 – Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART) and Immunexpress Pty Ltd (‘Immunexpress’), a host response molecular diagnostic company, committed to improving clinical and economic outcomes for suspected sepsis patients, today announce that they have entered into a...
International Sepsis Forum 2017
International Sepsis Forum 2017 11-13 September, 2017 Paris, France Dr Leo McHugh presented an algorithmic method for interpreting the performance of high accuracy diagnostics when judged against clinical diagnoses known to contain uncertainty. This is the first public release of this method and associated open-course software for the diagnostics community....
Differentiating sepsis and systemic inflammatory response syndrome using biomarkers
An interview with Dr. Richard Brandon, Chief Scientific Officer, Immunexpress, conducted by April Cashin-Garbutt, MA (Cantab).
A Four-Biomarker Blood Signature Discriminates Systemic Inflammation Due to Viral Infection Versus Other Etiologies
Sampson et al., Scientific Reports | Data demonstrates the ability of a four-biomarker blood signature to discriminate viral and non-viral causes of systemic inflammation in a variety of clinical settings. Discussed is the investigation of how to determine if a blood-based signature could be discovered and show a host systemic...
Four-Biomarker Signature Differentiates Viral and Non-Viral Causes of Systemic Inflammation
Results from an investigation of over 40 datasets published in Scientific Reports SEATTLE, June 6, 2017 /PRNewswire/ -- Immunexpress, Inc., a molecular diagnostic company with the first FDA cleared host response assay for suspected sepsis patients, today announced the publication, in Scientific Reports, of data demonstrating the ability of a four-biomarker...
European Molecular Diagnostics 2017
Molecular Diagnostics Europe 10-13 April 2017 Lisbon, Portugal. Dayle Sampson, Director of Bioinformatics at Immunexpress, presented on the Dynamics of Host Response in Severe Respiratory Illness. He described ongoing work at Immunexpress on using different signatures to understand the contribution of different pathogen classes to sepsis.
Diagnostic Accuracy of a Host Gene Expression Signature That Discriminates Clinical Severe Sepsis Syndrome and Infection-Negative Systemic Inflammation Among Critically Ill Children
Zimmerman et al., Critical Care Medicine | SeptiCyte Lab is able to discriminate clearly between clinically well-defined and homogeneous postcardiopulmonary bypass and clinically overt severe sepsis syndrome groups in children. A broader investigation among children with more heterogeneous inflammation-associated diagnoses and care settings is warranted.
Immunexpress wins FDA clearance for sepsis tests that could save billions of dollars
Immunexpress has won Food and Drug Administration clearance for a diagnostics test that could save hospitals billions of dollars. The FDA cleared SeptiCyte LAB analysis that tests for sepsis, a life-threatening immune response to infection.
FDA Clears SeptiCyte™ LAB for Suspected Sepsis Patients
The FDA granted 510(k) clearance to Immunexpress for the use of its SeptiCyte™ LAB as an aid in differentiating infection-positive (sepsis) from infection-negative (systemic inflammatory response syndrome, or SIRS) systemic inflammation in critically ill patients on their first day of intensive care unit admission.
FDA clears Immunexpress’ RNA-based, whole-blood sepsis Dx
Immunexpress earned 510(k) clearance for its RNA-based clinical diagnostic that detects sepsis in critically ill patients. The test, which uses whole blood, returns results in a few hours.
Immunexpress Receives FDA Clearance for Direct-From-Blood Sepsis Test
Revolutionary diagnostic SeptiCyte™ LAB cleared by FDA for suspected sepsis patients.
Revolutionary Diagnostic SeptiCyte™ LAB Cleared By FDA for Suspected Sepsis Patients
SEATTLE, Feb. 22, 2017 – Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and healthcare providers, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the use of SeptiCyte™ LAB as an aid in differentiating infection-positive (sepsis)...